The fully automatic computer program requires a maximum of 10 minutes per patient for the analysis of the magnetic resonance image of a brain tumour. A doctor requires between 30 and 60 minutes, however. As the first software worldwide to do so, BRaTumIA also examines the tumour on a three dimensional basis without the need for human support, a task a doctor would take a far longer time to complete, and with a higher risk of error. As a result, manual daily hospital measurements are now only
occurring on two levels.
The program was developed and clinically tested by a team of doctors and engineers from the Bern University Hospital and the Institute for Surgical Technology and Biomechanics (ISTB) at the University of Bern, under the leadership of professors Roland Wiest (University Institute for Neuroradiology) and Mauricio Reyes (ISTB).
Analysis Down to the Tiniest Detail
BraTumIA provides Neuroradiologists with the optimum support in their analysis. The software compares the patient’s MRI images with all of the previously gathered statistical data and determines the tissue structures of the malignant tumour right down to the tiniest detail. Prof. Roland Wiest, Neuroradiologist and Leader of the Support Centre of Advanced Neuroimaging at the Bern University Hospital: „The precision segmenting of the tumour tissue is enabling us to use the image information to optimise the treatment on an ever more precise basis. This is hugely important, as new treatment strategies for gliomas – malignant tumours – can receive exact information on the growth data
concerning the tumours.“
Data Mining: Learning Software
It is in this context that BraTumIA has joined the medical data mining trend. Similar to conventional data mining, in which data regarding customers‘ buying and reading habits are gathered in the internet, the software consistently improves through the constant gathering of new statistical data. BraTumIA is currently the focus of considerable international attention: the Washington Post used the software at the beginning of October to demonstrate data mining in the analytical medical sector – in international comparisons, the software has consistently achieved a top three position in terms of its measuring accuracy.
he possibility of being able to continuously ‚feed‘ the software with new statistical data is decisive for future brain tumour patients: when doctors analyse MRI images manually, analytical errors are theoretically possible in several different directions. The software, however, only makes analytical errors in the same direction, if at all. Doctors can check any such errors on a quick and targeted basis and reduce them to the minimum.
Soon to be Available for MS and Strokes
The intensive collaboration of the engineers and doctors in the development of BraTumIA could soon be benefitting to patients suffering from multiple sclerosis (MS) and those who have suffered stroke. The research group is currently working at full speed on two further versions of the software.
With MS patients, BraTumIA is set to provide precise analyses of inflamed brain tissue in the white brain matter (plaques). With stroke patients the software will serve the purpose of risk analysis: In the immediate aftermath of a stroke it recognises which parts of the brain are likely to remain damaged subsequent to treatment. In this task, BraTumIA also makes use of clinically gathered data.
The research on the computer supported analysis using BraTumIA at the Bern University Hospital and the University of Bern is being supported by the European Union, the Swiss National Fund and the Bern and Swiss Cancer League.